Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Upstream Bio is set to announce its Q2 2025 earnings on August 5th, projecting a loss of ($0.61) per share and revenue of $0.32 million.
• In its previous quarter, the company reported a loss of ($0.51) per share on revenue of $0.57 million, both below analysts' expectations.
• Analyst ratings for Upstream Bio have improved, with a recent upgrade from "sell" to "hold" and a consensus price target of $56.50.

Upstream Bio (NASDAQ:UPB - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Upstream Bio to post earnings of ($0.61) per share and revenue of $0.32 million for the quarter.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to analysts' expectations of $0.71 million. On average, analysts expect Upstream Bio to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Upstream Bio Trading Up 0.5%

UPB stock traded up $0.08 on Friday, reaching $15.39. 321,652 shares of the company's stock were exchanged, compared to its average volume of 343,225. The stock has a fifty day moving average of $11.13 and a 200-day moving average of $9.43. Upstream Bio has a twelve month low of $5.14 and a twelve month high of $29.46.

Analyst Ratings Changes

Separately, Wall Street Zen raised Upstream Bio from a "sell" rating to a "hold" rating in a report on Friday, June 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $56.50.

Institutional Investors Weigh In On Upstream Bio

A hedge fund recently raised its stake in Upstream Bio stock. Woodline Partners LP lifted its position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 557,063 shares of the company's stock after acquiring an additional 30,552 shares during the quarter. Woodline Partners LP owned 1.04% of Upstream Bio worth $3,409,000 as of its most recent SEC filing.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.